Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225380 · ClinicalTrials.gov registry record · Phase 2
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 324
- Enrollment target
NCT01225380 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 324 participants.
The verdict
NCT01225380, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 324 participants
- Enrollment target
Study Summary
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®). Additionally, the efficacy and safety of 24 weeks of GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) will be evaluated.
Interventions
- BIOLOGICAL Pegasys®
- DRUG Copegus®
- DRUG GS-9190
- DRUG GS-9256
- DRUG GS-9190 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225380
The ClinicalTrials.gov registry entry for NCT01225380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pegasys® is the first listed.
NCT01225380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225380 about?
NCT01225380 is a clinical study titled "A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C". This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®). Additionally, the efficacy and safety of 24 weeks of GS-9256 in combination with...
What is the current status of trial NCT01225380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 324 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01225380?
The interventions under investigation include: Pegasys® (BIOLOGICAL), Copegus® (DRUG), GS-9190 (DRUG), GS-9256 (DRUG), GS-9190 placebo (DRUG).
Who is sponsoring clinical trial NCT01225380?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.